Yahoo Sports’ Dan Wetzel and Pete Thamel, and Sports Illustrated’s Pat Forde discuss Kristen Saban Satos’ tweet saying that Ohio State is faking COVID cases to postpone their game against Alabama so QB Justin Fields can get fully healthy.
Yahoo Sports’ Dan Wetzel and Pete Thamel, and Sports Illustrated’s Pat Forde discuss Kristen Saban Satos’ tweet saying that Ohio State is faking COVID cases to postpone their game against Alabama so QB Justin Fields can get fully healthy.
Jonathan Ernst via ReutersROME—If you look closely at President Joe Biden’s credenza in his first Oval Office photo op, there is a carefully placed shot of the then-vice president shaking hands with Pope Francis after he was crowned pope in 2013. Biden flew to Rome for the papal coronation—and has regularly quoted the pontiff on the campaign trail, especially on race and economic disparities.And yet the placement of photo immediately drew ire among conservative Catholics, many of whom posted on social media that it was “opportunistic” to display a photo with the pope and still support abortion and LGBTQ rights. Many among the most conservative anti-Francis Catholic commentators have gone so far as to say Biden is complicit in the further destruction of the Catholic church but the Vatican is not likely to comment on matters seen as political. Those who have long-criticized this pope for opening up a dialogue on both abortion forgiveness and LGBTQ rights are the loudest opponents to the new U.S. president.The Plot to Bring Down Pope FrancisAs the second ever Catholic to be elected president after John F. Kennedy in 1960, Biden now has the dubious task of balancing his faith and his politics, which are worlds apart. And he won't have an easy time convincing any of the U.S. church’s hard-core conservatives that he should be recognized as a member of the Roman Catholic Church. St. Louis priest Michael O’Connor was quick to remind the conservative faithful that Biden “masquerades as a Catholic” and, as he has said in the past, “Joe Biden is an embarrassment to Catholicism.”On Inauguration Day, Archbishop Jose Gomez, president of U.S. Conference of Catholic Bishops, issued a damning statement about the new president, which angered the more liberal factions of the U.S. church and reportedly ruffled feathers in Rome. “Our new President has pledged to pursue certain policies that would advance moral evils and threaten human life and dignity,” he wrote. “Most seriously in the areas of abortion, contraception, marriage, and gender. Of deep concern is the liberty of the Church and the freedom of believers to live according to their consciences.”The statement was immediately rebuked by Francis-loving Catholics, including the influential Cardinal Blase Cupich of Chicago who tweeted, “Today, the U.S. Conference of Catholic Bishops issued an ill-considered statement on the day of President Biden’s inauguration,” he wrote. “Aside from the fact that there is seemingly no precedent for doing so, the statement, critical of President Biden, came as a surprise to many bishops, who received it just hours before it was released.” In other words, Gomez was not speaking for all the U.S. bishops.Today, the U.S. Conference of Catholic Bishops issued an ill-considered statement on the day of President Biden’s inauguration.— Cardinal Cupich (@CardinalBCupich) January 20, 2021 Massimo Faggioli, professor of historical theology at Villanova University and the author of the new book Joe Biden and Catholicism in the United States, told The Daily Beast that on some issues, Biden will have to navigate “a very difficult path between a religious constituency of moderates and a radical-progressive Democratic Party especially on ethical issues: abortion but also LGBT, religious liberty.”A case in point happened in November 2019 on the campaign trail, when Father Robert Morey, the priest at Saint Anthony Catholic Church in Florence, South Carolina, denied Biden Holy Communion over his stance on abortion. “Sadly, this past Sunday, I had to refuse Holy Communion to former Vice President Joe Biden,” Morey told the local media. “Holy Communion signifies we are one with God, each other and the church. Our actions should reflect that. Any public figure who advocates for abortion places himself or herself outside of church teaching.”Faggioli says Biden’s faith is more about witness than proclamation or proposition. “For Catholics anxious to see immediate results: this takes time to have an impact both on the church and in the public square. In some sense it’s similar to what is happening with Pope Francis’ pontificate,” he says, referring to the struggles this pope has had with hard core conservatives in the right wing of the church.Biden does have a fan in Pope Francis, whose own struggles with conservative Catholics are well documented. Francis was one of the first world leaders to send Biden congratulations both after his election and after his inauguration, which irked many conservatives who quietly campaigned to keep Trump in office. “At a time when the grave crises facing our human family call for farsighted and united responses, I pray that your decisions will be guided by a concern for building a society marked by authentic justice and freedom, together with unfailing respect for the rights and dignity of every person, especially the poor, the vulnerable and those who have no voice,” the pope wrote in his message to Biden Wednesday.The same pope once questioned Trump’s christianity when asked about his desire to build a wall on the U.S. southern border. “A person who thinks only about building walls, wherever they may be, and not of building bridges, is not Christian,” Francis said about Trump in 2017.Did Pope Francis Just Sink Trump?But having Francis on his side will not guarantee the support of Catholic Americans. On the contrary, Biden has been the subject of a campaign among conservatives who preferred Trump and who aren’t ready to accept Biden’s compromise Catholicism.“But there is something new,” Faggioli says. “Biden’s Catholicism represents a new synthesis between the integralist or Neo-medieval Catholic model of imposition of values from top on society—something we can call the Opus Dei model—and the 20th century assimilationist, often hidden Catholicism—like at the time of JFK and John Kerry.”In other words, Biden’s brand of Catholicism is more opaque—and closer to Francis. “This is part of the appeal because you may not agree with Joe Biden on all issues,” Faggioli says. “But I sense that many American believers can see something in his faith that is true, that is authentic in him.”Read more at The Daily Beast.Got a tip? Send it to The Daily Beast hereGet our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.
Gigit, Inc. (https://gigitsecurity.com), a cybersecurity firm that ensures cybersecurity compliance and reduces cybersecurity risk through its testing, assessment, and consulting services, today announces the formal merger of Peak InfoSec (https://peakinfosec.com), an Information Security consulting firm and turnaround specialists, into its company. Peak InfoSec will act as a wholly-owned subsidiary of Gigit, providing Cybersecurity Maturity Model Certification (CMMC) Third-Party Assessor Organization (C3PAO) conformity assessments to Gigit's clients that are part of the Defense Industrial Base. This is the second merger Gigit will have completed, having previously acquired Cyber51, a greatly-regarded cybersecurity company with a focus on network & web application vulnerability assessments, penetration testing ("pentesting"), and cybersecurity training. With this latest merger, Peak InfoSec founder and highly-certified cybersecurity expert, Matthew Titcombe, steps into the role of Chief Security Information Officer (CISO) at Gigit. Gigit, which among its specializations itself offers cybersecurity due diligence services in the mergers and acquisitions space, furthers its ability to serve mid-market (Interim Healthcare) and large (Uber) clients heavily involved in M&A; as well as federal government contracting work.
The US Navy Veterans Mesothelioma Advocate says, "We want a Navy Veteran with mesothelioma or their family to get serious about financial compensation, and to call attorney Erik Karst of the law firm of Karst von Oiste at 800-714-0303 for his serious approach to compensation for a person like this. Frequently mesothelioma compensation for a Navy Veteran can exceed a million dollars. Mesothelioma compensation for a Navy Veteran is based on how, where and when they were exposed to asbestos.
Solskjaer plans to lean on his squad players in the FA Cup.
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2021) - GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) ("GoldHaven" or the "Company") reports that GoldHaven crews are finalizing preparations for Rio Loa to commence GOH's 5000m Phase I drill program. GOH crews are also mobilizing equipment to conduct a trenching program at the Coya, Alicia and Roma projects to include rock sampling and geophysics. Trenching conducted at Rio Loa in December 2020 ...
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce its inclusion in the Horizon North American Psychedelic ETF, the first ever psychedelic ETF of its kind. The new ETF is expected to start trading January 26, 2021 under the symbol "PYSK" on the NEO exchange.The ...
AUSTIN, Texas, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Phunware, Inc. (NASDAQ: PHUN) (“Phunware” or “the Company”) a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, will be presenting at the Proactive Investors One2One Investor Forum, which is being held virtually on January 26, 2021. Phunware COO Randall Crowder is scheduled to present on Tuesday, January 26 at 1:00 p.m. Eastern time. The presentation will be webcast live here and available for replay here. To receive additional information, please contact Phunware’s IR team at PHUN@gatewayir.com. About Phunware, Inc. Everything You Need to Succeed on Mobile — Transforming Digital Human Experience Phunware, Inc. (NASDAQ: PHUN), is the pioneer of Multiscreen-as-a-Service (MaaS), an award-winning, fully integrated enterprise cloud platform for mobile that provides companies the products, solutions, data and services necessary to engage, manage and monetize their mobile application portfolios and audiences globally at scale. Phunware’s Software Development Kits (SDKs) include location-based services, mobile engagement, content management, messaging, advertising, loyalty (PhunCoin & Phun) and analytics, as well as a mobile application framework of pre-integrated iOS and Android software modules for building in-house or channel-based mobile application and vertical solutions. Phunware helps the world’s most respected brands create category-defining mobile experiences, with more than one billion active devices touching its platform each month. For more information about how Phunware is transforming the way consumers and brands interact with mobile in the virtual and physical worlds visit www.phunware.com, www.phuncoin.com, www.phuntoken.com, and follow @phunware, @phuncoin and @phuntoken on all social media platforms. Investor Relations Contact:Matt Glover and John YiGateway Investor RelationsEmail: PHUN@gatewayir.comPhone: (949) 574-3860 PR & Media Inquiries:Email: firstname.lastname@example.orgPhone: (512) 693-4199
Scottsdale, Arizona--(Newsfile Corp. - January 22, 2021) - TriStar Gold Inc. (TSXV: TSG) (the Company or TriStar) is pleased to announce the appointment of Ms. Jessica Van Den Akker to the Board of Directors as an independent director. Jessica will also act as chairperson of the audit committee. Mr. Brian Irwin will be standing down from the Board of Directors but will continue to act as corporate secretary."First, I would like to ...
Evans Bancorp (NYSE American: EVBN) Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast
Hodes Weill & Associates (Hodes Weill), a global advisory firm focused on the real estate investment and funds management industry, is pleased to announce that Matt Hershey has become a Partner of the firm. In this role, Matt will continue to work with institutional investors across the range of Hodes Weill’s offerings and transactions. In addition, he will assume responsibility for overseeing the firm’s global team of institutional coverage and distribution professionals, as the Global Head of Distribution.
United Legwear & Apparel Co. (ULAC) has acquired TicTacToe, a brand of infant, toddler, and children's legwear, accessories and apparel that has been a trusted staple in childrenswear for over 30 years.
Cloudbreak Health, LLC ("Cloudbreak"), a leading telehealth and video remote interpretation solutions provider, today announced that GigCapital2, Inc. ("GigCapital2") (NYSE:GIX) has raised $285 million for its previously announced business combinations with UpHealth Holdings, Inc. ("UpHealth") and Cloudbreak. This capital raise includes an aggregate of 3,000,000 shares of GigCapital2 common stock at $10.00 per share and $255,000,000 of 5-year unsecured convertible notes which shall bear interest at a rate of 6.25% per annum, and are convertible into common shares of the combined company, UpHealth, Inc., at a conversion price of $11.50.
The "Organic Fertilizers Market Research Report: By Crop Type (Cereals & Grains, Oilseeds & Pulses, Fruits & Vegetables) - Global Industry Analysis and Demand Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
Sunstone Hotel Investors, Inc. (the "Company" or "Sunstone") (NYSE: SHO), the owner of Long-Term Relevant Real Estate® in the hospitality sector, announced the following tax treatment of the 2020 distributions to holders of the Company's common and preferred stock.
MobiCard is an all-in-one digital application for networking, lead generation analytics, and business card exchange and connects businesses with other businesses or potential customers.
Dun & Bradstreet Holdings, Inc. ("Dun & Bradstreet") (NYSE:DNB), a leading global provider of business decisioning data and analytics, today announced the date for the release of its fourth quarter and full-year 2020 earnings and its participation in upcoming investor conferences.
GoodWest Industries, LLC, a manufacturer and supplier of aseptic beverages and foodservice dispensing solutions, primarily selling shelf-stable and bag-in-box coffee creamer and iced coffee, today announced the appointment of Quenten Wentworth as Chief Executive Officer. Mr. Wentworth succeeds Rick Lawlor, who becomes Executive Chairman.
Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseasesBOSTON, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today joins the Alagille community in commemorating the second annual International Alagille Syndrome Awareness Day on January 24, 2021 in honor of Dr. Daniel Alagille's birthday. Alagille syndrome (ALGS) is a rare genetic disorder that can affect the liver, heart and other parts of the body. Albireo leaders reaffirm the Company’s commitment to advancing life-changing research and join the community in bringing greater awareness to patients and families affected by this rare and devastating disorder. “Connecting with families who manage Alagille syndrome and hearing firsthand the burdens associated with the disease reaffirms our mission at Albireo, which is to provide hope and improve treatment options and outcomes for children and families with rare cholestatic liver diseases,” said Ron Cooper, President and Chief Executive Officer of Albireo. “Their feedback has been invaluable in helping design our Phase 3 study in Alagille syndrome, called ASSERT, which is currently enrolling eligible patients.” Alagille syndrome Alliance (ALGSA) is an international advocacy group representing patients and families. The nonprofit facilitates in-person and digital forums to increase community education and awareness among families, healthcare providers and scientists. ALGSA also provides assistance programs to families in need and sponsors grants to advance scientific research. To recognize International Alagille Syndrome Awareness Day, the organization will be hosting a 24-hour “Aware-A-Thon” with the objective of connecting families in raising awareness of ALGS through sharing stories via social media. For more information, visit www.alagille.org, or find the ALGSA on social media under @ALGSAlliance. “The Alagille syndrome community is one of tremendous courage, determination and camaraderie. Our support groups with families spanning the globe are filled with people dealing with all phases and aspects of the syndrome. They encourage, lift up, lean on, educate and help one another in so many ways,” said Roberta Smith, President of Alagille Syndrome Alliance. “In honor of our families, International Alagille Syndrome Awareness Day is a day to elevate the patient voice, with focus on disease awareness and highlighting Alagille education resources for all stakeholders as well as new families stepping into this complex rare disease diagnosis.” About ALGSAlagille syndrome (ALGS) is a rare, multisystem genetic disorder that can affect the liver, heart, skeleton, eyes, central nervous system, kidneys and facial features. Liver damage is caused by a paucity of bile ducts preventing bile flow from the liver to the small intestine. Approximately 95% of patients with ALGS present with chronic cholestasis, usually within the first three months of life, and up to 88% also present with severe, intractable pruritus. Currently, there are no approved drug treatments. About AlbireoAlbireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases. The company recently completed U.S. and EU regulatory submissions for odevixibat in patients with progressive familial intrahepatic cholestasis (PFIC), and anticipates potential regulatory approvals, issuance of a rare pediatric disease priority review voucher and launch in the second half of 2021. Odevixibat is also currently being evaluated in the ASSERT Phase 3 trial in ALGS, BOLD Phase 3 trial in patients with biliary atresia and the ongoing PEDFIC 2 Phase 3 open-label trial in patients with PFIC. The Company also completed IND-enabling studies for new preclinical candidate A3907 and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo: www.albireopharma.com. Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements, other than statements of historical fact, regarding, among other things: the plans for, or progress, scope, cost, initiation, duration, enrollment, results or timing for availability of results of, development of odevixibat or any other Albireo product candidate or program, including regarding expectations regarding the impact of COVID-19 on our business and our ability to adapt our approach as appropriate; the Phase 3 clinical program for odevixibat in patients with PFIC, the pivotal trial for odevixibat in biliary atresia (BOLD), and the pivotal trial for odevixibat in Alagille syndrome (ASSERT); the target indication(s) for development or approval, the size, design, population, location, conduct, cost, objective, enrollment, duration or endpoints of any clinical trial, or the timing for initiation or completion of or availability or reporting of results from any clinical trial, including the long-term open-label extension study for odevixibat in PFIC, the pivotal trial for odevixibat in biliary atresia, the pivotal trial for odevixibat in Alagille syndrome; the potential approval and commercialization of odevixibat; discussions with the FDA or EMA regarding our programs; the potential benefits or competitive position of odevixibat or any other Albireo product candidate or program or the commercial opportunity in any target indication; the potential effects of odevixibat of the treatment of PFIC patients and its potential to improve the current standard of care; the potential benefits of an orphan drug designation; the potential issuance of a rare pediatric disease priority review voucher; or Albireo’s plans, expectations or future operations, financial position, revenues, costs or expenses. Albireo often uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “planned,” “continue,” “guidance,” and similar expressions to identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to: negative impacts of the COVID-19 pandemic, including on manufacturing, supply, conduct or initiation of clinical trials, or other aspects of our business; whether favorable findings from clinical trials of odevixibat to date, including findings in indications other than PFIC, will be predictive of results from other clinical trials of odevixibat; whether either or both of the FDA and EMA will determine that the primary endpoint for their respective evaluations and treatment duration of the double-blind Phase 3 trial in patients with PFIC are sufficient to support approval of odevixibat in the United States or the European Union, to treat PFIC, a symptom of PFIC, a specific PFIC subtype(s) or otherwise; the outcome and interpretation by regulatory authorities of the ongoing third-party study pooling and analyzing of long-term PFIC patient data; the timing for initiation or completion of, or for availability of data from, clinical trials of odevixibat, including the pivotal program in biliary atresia or the pivotal program in Alagille syndrome, and the outcomes of such trials; Albireo’s ability to obtain coverage, pricing or reimbursement for approved products in the United States or European Union; delays or other challenges in the recruitment of patients for, or the conduct of, company’s clinical trials; and Albireo’s critical accounting policies. These and other risks and uncertainties that Albireo faces are described in greater detail under the heading “Risk Factors” in Albireo’s most recent Annual Report on Form 10-K or in subsequent filings that it makes with the Securities and Exchange Commission. As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur. Albireo cautions you not to place undue reliance on any forward-looking statement. In addition, any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law. Media Contact:Colleen Alabiso, 857-356-3905, email@example.comLisa Rivero, 617-947-0899, firstname.lastname@example.org Investor Contact:Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
Fauquier Bankshares, Inc. (the "Company") (NASDAQ: FBSS), parent company of The Fauquier Bank (the "Bank"), reported net income of $1.4 million, or $0.36 per diluted share for the fourth quarter, compared with $1.5 million, or $0.41 per diluted share for the prior quarter and $1.6 million or $0.41 per diluted share for the fourth quarter of 2019. For the twelve months ended December 31, 2020, net income was $5.9 million, or $1.55 per diluted share, compared with $6.8 million, or $1.80 per diluted share for the twelve months ended December 31, 2019.
Wenzhou, China, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Huadi International Group Co., Ltd. (“HUDI” or the “Company”) (NASDAQ: HUDI), a leading developer and manufacturer of industrial stainless steel seamless pipes and tubes products in China, today announced the pricing of its initial public offering of 3,125,000 ordinary shares at a public offering price of $8.00 per ordinary share, for total gross proceeds of $25 million before deducting underwriting discounts and commissions and offering expenses. The offering is being conducted on a firm commitment basis. The ordinary shares have been approved for listing on The Nasdaq Capital Market and are expected to commence trading today, January 22, 2021, under the ticker symbol “HUDI.” The Company has granted the underwriters an option, exercisable within 45 days from the date of the underwriting agreement, to purchase up to an additional 468,750 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on January 26, 2021, subject to customary closing conditions. Craft Capital Management LLC and R.F. Lafferty & Co. Inc. are acting as joint book runners and Craft Capital Management LLC is also acting as the lead underwriter for the offering. Valuable Capital Limited and Shengang Securities Company Limited are acting as co-underwriters for the offering. Ortoli Rosenstadt LLP is acting as counsel to the Company, and Bevilacqua PLLC is acting as counsel to Craft Capital Management LLC. The Company intends to use the proceeds from this offering primarily for (i)product research and development, (ii) marketing and business development, (iii) new production equipment purchase, (iv) new business assessment and acquisition, and (v) talent acquisition and training and working capital. A registration statement on Form F-1 (File No. 333-248919) relating to the offering has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective by the SEC on December 30, 2020. The offering is being made only by means of a prospectus, forming a part of the registration statement. Copies of the prospectus related to the offering may be obtained, when available, from Craft Capital Management LLC by email at email@example.com or via standard mail to Craft Capital Management LLC, 377 Oak Street, Suite 402, Garden City, NY 11530. In addition, a copy of the final prospectus relating to the offering may be obtained via the SEC's website at www.sec.gov. Before you invest, you should read the final prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Huadi International Group Co., Ltd. Huadi International Group Co., Ltd. is a leading manufacturer of industrial stainless steel seamless pipes and tubes products with extensive distribution facilities and network for over twenty provinces in China and also with a big presence across international steel pipes industry. It offers a broad range of products exported to twenty countries and regions such as United States, Mexico, Thailand, Australia, Argentina, Taiwan, India, the Philippines, UAE and Canada. Its products are widely used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, electricity, automobile, naval architecture, paper mill and mechanical industries. For more information about the Company, please visit: http://www.huadi.cc. Forward-Looking Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Specifically, the Company’s statements regarding trading on the NASDAQ Capital Market and closing the initial public offering are forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; financial condition and results of operations; product and service demand and acceptance; reputation and brand; the impact of competition and pricing; changes in technology; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward‐looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: The Company:IR DepartmentEmail: IR@huadigroup.com Investor Relations:Janice Wang EverGreen Consulting Inc. Email: IR@changqingconsulting.comPhone: +86 13811768559